Top Ten most popular articles on Pharmafile.com this week
pharmafile | May 26, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | top ten
Among other things, it’s been a week characterised by safety failures as three of our most popular stories centred on adverse events. Pfizer is facing a $3.5 million lawsuit over allegations its arthritis treatment Celebrex causes heart issues and strokes, while Amgen’s osteoporosis drug failed its recent Phase 3 trial on safety risks, and perhaps most shockingly, a number of patients have died using Abbott Laboratories’ HeartMate II blood pumps.
On the positive side, Inovio announced “exceptional” results in a recent trial of its new HIV vaccine, while PwC’s PwC four strategies for creating value in life sciences – as featured in our new edition of Pharmafile – proved popular with readers this week.
Check out the week’s ten most popular articles on Pharmafile.com now!
10. J&J launches lawsuit to block release of Remicade biosimilar
Samsung Bioepis gained approval to launch its biosimilar to Johnson & Johnson’s Remicade just last month, on 21 April, but faces a legal challenge from the same company.
9. Brain drain: The experts the UK may lose due to Brexit
The regulatory and drug approval process is destined to change once the UK leaves the EU. The problem is, nobody is quite sure how things will change and how they should react in turn.
8. Inovio posts “exceptional” results for HIV vaccine
Inovio has posted strong results from the latest of its trial examining its potential HIV vaccine, with figures the company called “exceptional”.
7. AbbVie suffers knock to Humira patent
Coherus has won a victory against the patents protecting the release of a biosimilar version of AbbVie’s Humira.
6. 70 patients sue Pfizer over arthritis drug risks
Pfizer has been hit with a £3.5 million lawsuit by 70 Scottish patients who claim that the use of its drug Celebrex, for the treatment of muscle pain and joint stiffness associated with arthritis, led them to experience heart problems and multiple strokes.
5. Amgen hit by major safety blow on osteoporosis drug
Amgen and UCB SA have been delivered a crushing blow in its attempt to have a drug for osteoporosis approved in 2017, with new data from a Phase 3 clinical trial showing a previously unobserved increase in the risk for a cardiovascular serious adverse event.
4. AstraZeneca sells off rights to beta-blocker for $300 million
AstraZeneca announced that it had sold the European rights to its drug, Seloken (metoprolol), to Italian pharmaceutical company Recordati. The deal sees AZ receive $300 million for the rights, alongside further royalties.
3. Novartis cuts 500 traditional roles for 350 ‘high-tech’ ones
Novartis has announced the transfer or loss of 500 traditional production and development roles at its Swiss sites as it looks to add 350 others in high tech areas.
2. 26 die after attempting to replace Abbott’s blood pump controller themselves
At least 26 advanced heart failure patients have died and 19 have been injured by attempting to change the controller on Abbott Laboratories’ HeartMate II blood pumps themselves at home.
1. Pharma’s Identity Crisis: Four strategies for creating value in life sciences
As the demands of healthcare across the world begin to rise, PwC outlines four strategies for creating value in life sciences.
Related Content
Top Ten most popular articles on Pharmafile.com this week
As the year winds to a close, excitement is rising around the efficacy and availability …
Top Ten most popular articles on Pharmafile.com this week
The top ten news stories this week focus on herd immunity, as the Director of …
Pharmafile.com’s weekly COVID-19 news round-up
The coronavirus news this week focuses on the development of treatments to alleviate symptoms of …
